mRNA |
LY-2157299 |
CTRPv2 |
pan-cancer |
AAC |
-0.13 |
0.09 |
mRNA |
AZD0530 |
CCLE |
pan-cancer |
AAC |
0.08 |
0.1 |
mRNA |
DBeQ |
CTRPv2 |
pan-cancer |
AAC |
0.063 |
0.1 |
mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.055 |
0.1 |
mRNA |
BRD-K61166597 |
CTRPv2 |
pan-cancer |
AAC |
-0.053 |
0.1 |
mRNA |
AT-406 |
CTRPv2 |
pan-cancer |
AAC |
0.079 |
0.1 |
mRNA |
BRD-K55116708 |
CTRPv2 |
pan-cancer |
AAC |
-0.061 |
0.1 |
mRNA |
navitoclax:pluripotin (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.06 |
0.1 |
mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.056 |
0.1 |
mRNA |
Erlotinib |
CCLE |
pan-cancer |
AAC |
0.075 |
0.1 |